{"id":354696,"date":"2025-08-28T12:25:47","date_gmt":"2025-08-28T12:25:47","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-royalty-pharma\/"},"modified":"2025-08-28T12:25:47","modified_gmt":"2025-08-28T12:25:47","slug":"how-to-buy-royalty-pharma","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/","title":{"rendered":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-354696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Royalty Pharma plc (RPRX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, 2025 tahminleri ve maksimum getiri i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma rehberi ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Royalty Pharma plc (RPRX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, 2025 tahminleri ve maksimum getiri i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma rehberi ile \u00f6\u011frenin."},"intro":"\u0130la\u00e7 telif hakk\u0131 alan\u0131na yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Royalty Pharma plc (RPRX), geleneksel ila\u00e7 geli\u015ftirme riskleri olmadan \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lardan kar etme f\u0131rsat\u0131 sunar. Bu yenilik\u00e7i \u015firket, d\u00fcnyan\u0131n en ba\u015far\u0131l\u0131 tedavilerinin telif haklar\u0131na sahiptir ve siz uyurken bile d\u00fczenli nakit ak\u0131\u015f\u0131 yarat\u0131r. RPRX'in neden dikkatinizi hak etti\u011fini ve bug\u00fcn nas\u0131l hissedar olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130la\u00e7 telif hakk\u0131 alan\u0131na yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Royalty Pharma plc (RPRX), geleneksel ila\u00e7 geli\u015ftirme riskleri olmadan \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lardan kar etme f\u0131rsat\u0131 sunar. Bu yenilik\u00e7i \u015firket, d\u00fcnyan\u0131n en ba\u015far\u0131l\u0131 tedavilerinin telif haklar\u0131na sahiptir ve siz uyurken bile d\u00fczenli nakit ak\u0131\u015f\u0131 yarat\u0131r. RPRX'in neden dikkatinizi hak etti\u011fini ve bug\u00fcn nas\u0131l hissedar olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Royalty Pharma Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>28 A\u011fustos 2025 itibar\u0131yla Royalty Pharma plc (RPRX), NASDAQ borsas\u0131nda <strong>35,97 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin - \u015firket bu tarihte piyasa a\u00e7\u0131lmadan \u00f6nce 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak, bu duyurular \u00f6nemli fiyat hareketleri yarat\u0131r ve bilgili yat\u0131r\u0131mc\u0131lar bundan faydalanabilir.<\/p> <p><strong>Kazan\u00e7 Raporlar\u0131n\u0131n RPRX Hisse Performans\u0131na Etkisi:<\/strong><\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>37,01 $<\/td><td>Kar\u0131\u015f\u0131k tepki (EPS beklentiyi a\u015ft\u0131, gelir beklentisi ka\u00e7t\u0131)<\/td><\/tr> <tr><td>8 May 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>34,50 $<\/td><td>%8 art\u0131\u015f (g\u00fc\u00e7l\u00fc portf\u00f6y b\u00fcy\u00fcmesi)<\/td><\/tr> <tr><td>12 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>32,80 $<\/td><td>%12 art\u0131\u015f (yol g\u00f6sterici art\u0131\u015f\u0131)<\/td><\/tr> <tr><td>7 Kas 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>29,40 $<\/td><td>%6 art\u0131\u015f (telif hakk\u0131 \u00e7e\u015fitlendirmesi)<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>31,20 $<\/td><td>%4 d\u00fc\u015f\u00fc\u015f (ge\u00e7ici d\u00fc\u015f\u00fc\u015f)<\/td><\/tr> <tr><td>9 May 2024<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>28,90 $<\/td><td>%8 art\u0131\u015f (sat\u0131n alma haberi)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc:<\/strong> RPRX genellikle kazan\u00e7lar etraf\u0131nda %5-12 fiyat dalgalanmalar\u0131 ya\u015far ve olumlu s\u00fcrprizler kal\u0131c\u0131 yukar\u0131 y\u00f6nl\u00fc ivme yarat\u0131r. Son 2. \u00e7eyrek 2025 sonu\u00e7lar\u0131 karma\u015f\u0131k bir tablo g\u00f6sterdi - \u015firket EPS tahminlerini 0,04 $ a\u015farken gelir beklentilerini ka\u00e7\u0131rd\u0131; bu da yat\u0131r\u0131mc\u0131lar\u0131n \u00e7eyreklik dalgalanmalardan \u00e7ok uzun vadeli telif hakk\u0131 b\u00fcy\u00fcmesine odakland\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h2> <p>Royalty Pharma hisseleri son alt\u0131 ayda etkileyici <strong>%40+ getiri<\/strong> sa\u011flad\u0131:<\/p> <p><strong>Mart 2025:<\/strong> 25,54 $ (k\u0131\u015f sonras\u0131 toparlanma d\u00f6nemi)<br> <strong>Nisan 2025:<\/strong> 28,90 $ (1. \u00e7eyrek kazan\u00e7 beklentisi art\u0131\u015f\u0131)<br> <strong>May\u0131s 2025:<\/strong> 34,50 $ (g\u00fc\u00e7l\u00fc 1. \u00e7eyrek sonu\u00e7lar\u0131 ile %20 portf\u00f6y b\u00fcy\u00fcmesi)<br> <strong>Haziran 2025:<\/strong> 36,80 $ (telif hakk\u0131 modelinin piyasa taraf\u0131ndan tan\u0131nmas\u0131)<br> <strong>Temmuz 2025:<\/strong> 37,50 $ (yaz konsolidasyon d\u00f6nemi)<br> <strong>A\u011fustos 2025:<\/strong> 35,97 $ (2. \u00e7eyrek kazan\u00e7lar\u0131n\u0131n sindirilmesinden sonra mevcut seviye)<\/p> <p>Bu ola\u011fan\u00fcst\u00fc performans birka\u00e7 \u00f6nemli fakt\u00f6re dayan\u0131yor:<\/p> <ul> <li><strong>Portf\u00f6y gelirleri y\u0131ll\u0131k bazda %20 artarak<\/strong> 2. \u00e7eyrekte 727 milyon $ oldu<\/li> <li><strong>Telif hakk\u0131 \u00e7e\u015fitlendirme stratejisi<\/strong> yat\u0131r\u0131mc\u0131 g\u00fcvenini art\u0131r\u0131yor<\/li> <li><strong>\u0130\u00e7selle\u015ftirme i\u015flemi tamamland\u0131<\/strong>, i\u015fletme maliyetleri %10'dan %9-9,5'a d\u00fc\u015ft\u00fc<\/li> <li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>, 885 milyon $ de\u011ferindeki Imdelltra anla\u015fmas\u0131 gibi stratejik sat\u0131n almalara olanak sa\u011fl\u0131yor<\/li> <\/ul>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu Hedefi:<\/strong> 42-46 $ (mevcut 45,33 $ analist konsens\u00fcs\u00fcne dayanarak %25,99 y\u00fckseli\u015f potansiyeli) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/p> <p><strong>2026 Tahmini:<\/strong> 48-54 $ (telif portf\u00f6y\u00fcn\u00fcn olgunla\u015fmas\u0131 ve yeni sat\u0131n almalar)<br> <strong>2028 Projeksiyonu:<\/strong> 58-65 $ (s\u00fcrekli telif b\u00fcy\u00fcmesi ve piyasa geni\u015flemesi)<br> <strong>2030 Vizyonu:<\/strong> 70-80 $ (sekt\u00f6r liderli\u011fi pozisyonu ve k\u00fcresel sa\u011fl\u0131k trendleri)<\/p> <p>Y\u00fckseli\u015f beklentisi, Royalty Pharma'n\u0131n benzersiz i\u015f modeli taraf\u0131ndan destekleniyor - geli\u015ftirme risklerini \u00fcstlenmeden ba\u015far\u0131l\u0131 ila\u00e7lardan kar ediyorlar. 35'ten fazla ticari terapi ve 14 geli\u015ftirme a\u015famas\u0131nda aday ile \u015firket, piyasa dalgalanmalar\u0131nda istikrar sa\u011flayan \u00e7oklu gelir ak\u0131\u015flar\u0131na sahip.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p> <ul> <li><strong>7,8 milyar $ bor\u00e7 y\u00fck\u00fc<\/strong>, y\u0131ll\u0131k 275 milyon $ faiz y\u00fck\u00fcml\u00fcl\u00fc\u011f\u00fc yarat\u0131yor<\/li> <li><strong>Promacta gibi ana \u00fcr\u00fcnler i\u00e7in jenerik rekabet tehditleri<\/strong><\/li> <li><strong>\u0130la\u00e7 fiyatland\u0131rma politikalar\u0131 (MFN sonu\u00e7lar\u0131) \u00e7evresinde d\u00fczenleyici belirsizlik<\/strong><\/li> <li><strong>3 milyar $ agresif hisse geri al\u0131m program\u0131 ile sermaye tahsis zorluklar\u0131<\/strong><\/li> <\/ul> <p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p> <ul> <li><strong>Son 885 milyon $ tutar\u0131ndaki Imdelltra telif hakk\u0131 sat\u0131n al\u0131m\u0131<\/strong> (<a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-reports-second-quarter-2025-results\/\">2. \u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>Y\u0131ll\u0131k bazda %20 portf\u00f6y gelir art\u0131\u015f\u0131<\/strong><\/li> <li><strong>%2,39-2,45 temett\u00fc verimi<\/strong> ve d\u00fczenli \u00e7eyreklik \u00f6demeler<\/li> <li><strong>Biyoteknoloji sekt\u00f6r\u00fcne k\u0131yasla d\u00fc\u015f\u00fck volatilite profili<\/strong> (beta 0,54)<\/li> <li><strong>\u0130\u00e7selle\u015ftirme tamamland\u0131<\/strong>, operasyonel maliyetler \u00f6nemli \u00f6l\u00e7\u00fcde azald\u0131<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>Dollar-cost averaging ile k\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in haftal\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Kas\u0131m kazan\u00e7lar\u0131 \u00f6ncesi cazip giri\u015f noktalar\u0131 i\u00e7in 34-36 $ aras\u0131nda fiyat uyar\u0131lar\u0131 kurun<\/strong><\/li> <li><strong>Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %5-10'unu RPRX'e ay\u0131r\u0131n<\/strong> - uygun \u00e7e\u015fitlendirme i\u00e7in<\/li> <li><strong>5 Kas\u0131m kazan\u00e7lar\u0131n\u0131 yak\u0131ndan takip edin<\/strong> - tarihsel olarak en iyi al\u0131m f\u0131rsatlar\u0131n\u0131 yarat\u0131r<\/li> <\/ol> <p>Mizahi t\u00fcccar bilgeli\u011fi: \"RPRX ticareti yapmak, telif hakk\u0131 toplamak gibidir - hitlerin gelmeye devam etmesini istersiniz ve d\u00fczenli gelirin tad\u0131n\u0131 \u00e7\u0131kar\u0131rs\u0131n\u0131z. Sadece her \u00e7eyre\u011fin liste ba\u015f\u0131 single olmas\u0131n\u0131 beklemeyin!\"<\/p>  <h2>\u2705 Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"RPRX\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fruluk i\u00e7in tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Son onay \u00f6ncesi komisyon oranlar\u0131n\u0131 kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonu izleyin<\/td><td>Fiyat hedefleri ve zarar durdurma uyar\u0131lar\u0131 kurun<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> - stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda KYC s\u00fcreci<\/strong> - tek bir belge ile dakikalar i\u00e7inde do\u011frulama<\/li> <li><strong>Y\u00fczlerce para \u00e7ekme y\u00f6ntemi<\/strong> - kripto paralardan geleneksel bankac\u0131l\u0131\u011fa kadar<\/li> <li><strong>Kullan\u0131c\u0131 dostu aray\u00fcz<\/strong> - piyasalar\u0131 \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in \u00f6zel tasar\u0131m<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, Royalty Pharma gibi \u015firketlerde pozisyon olu\u015fturmak isteyen ve piyasa dinamiklerini \u00f6\u011frenen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>  <h2>\ud83c\udf0d 2025'te Royalty Pharma: Sa\u011fl\u0131k Finansman\u0131n\u0131n Sessiz Devi<\/h2> <p>Royalty Pharma, yat\u0131r\u0131mc\u0131lar\u0131n ila\u00e7 inovasyonuna kat\u0131l\u0131m \u015feklini devrim niteli\u011finde de\u011fi\u015ftirdi. Bireysel ila\u00e7 geli\u015ftirmeye bahis yapmak yerine, \u015firket ba\u015far\u0131l\u0131 tedavilerin telif haklar\u0131n\u0131 sat\u0131n alarak \u00e7oklu terap\u00f6tik alanlarda gi\u015fe rekorlar\u0131 k\u0131ran ila\u00e7lardan \u00e7e\u015fitlendirilmi\u015f gelir ak\u0131\u015f\u0131 yarat\u0131yor.<\/p> <p>\u015eirket \u015fu anda kanser, nadir hastal\u0131klar ve kronik durumlar i\u00e7in tedaviler dahil olmak \u00fczere 35'ten fazla ticari \u00fcr\u00fcn\u00fcn haklar\u0131na sahip. Amgen'in k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an imm\u00fcnoterapisi Imdelltra'n\u0131n 885 milyon $ tutar\u0131ndaki son sat\u0131n al\u0131m\u0131, d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc ila\u00e7lara stratejik odaklar\u0131n\u0131 g\u00f6steriyor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Royalty Pharma'n\u0131n portf\u00f6y\u00fc, d\u00fcnya genelinde yakla\u015f\u0131k her 100 hastadan 1'ini tedavi eden ila\u00e7lardan telif hakk\u0131 al\u0131yor. Gelir modeli, onlar\u0131 geleneksel biyoteknoloji riskleri olmadan sa\u011fl\u0131k inovasyonunun ortaklar\u0131 yap\u0131yor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Royalty Pharma Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>28 A\u011fustos 2025 itibar\u0131yla Royalty Pharma plc (RPRX), NASDAQ borsas\u0131nda <strong>35,97 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin &#8211; \u015firket bu tarihte piyasa a\u00e7\u0131lmadan \u00f6nce 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak, bu duyurular \u00f6nemli fiyat hareketleri yarat\u0131r ve bilgili yat\u0131r\u0131mc\u0131lar bundan faydalanabilir.<\/p>\n<p><strong>Kazan\u00e7 Raporlar\u0131n\u0131n RPRX Hisse Performans\u0131na Etkisi:<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>37,01 $<\/td>\n<td>Kar\u0131\u015f\u0131k tepki (EPS beklentiyi a\u015ft\u0131, gelir beklentisi ka\u00e7t\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>34,50 $<\/td>\n<td>%8 art\u0131\u015f (g\u00fc\u00e7l\u00fc portf\u00f6y b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<tr>\n<td>12 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>32,80 $<\/td>\n<td>%12 art\u0131\u015f (yol g\u00f6sterici art\u0131\u015f\u0131)<\/td>\n<\/tr>\n<tr>\n<td>7 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>29,40 $<\/td>\n<td>%6 art\u0131\u015f (telif hakk\u0131 \u00e7e\u015fitlendirmesi)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>31,20 $<\/td>\n<td>%4 d\u00fc\u015f\u00fc\u015f (ge\u00e7ici d\u00fc\u015f\u00fc\u015f)<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>28,90 $<\/td>\n<td>%8 art\u0131\u015f (sat\u0131n alma haberi)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc:<\/strong> RPRX genellikle kazan\u00e7lar etraf\u0131nda %5-12 fiyat dalgalanmalar\u0131 ya\u015far ve olumlu s\u00fcrprizler kal\u0131c\u0131 yukar\u0131 y\u00f6nl\u00fc ivme yarat\u0131r. Son 2. \u00e7eyrek 2025 sonu\u00e7lar\u0131 karma\u015f\u0131k bir tablo g\u00f6sterdi &#8211; \u015firket EPS tahminlerini 0,04 $ a\u015farken gelir beklentilerini ka\u00e7\u0131rd\u0131; bu da yat\u0131r\u0131mc\u0131lar\u0131n \u00e7eyreklik dalgalanmalardan \u00e7ok uzun vadeli telif hakk\u0131 b\u00fcy\u00fcmesine odakland\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h2>\n<p>Royalty Pharma hisseleri son alt\u0131 ayda etkileyici <strong>%40+ getiri<\/strong> sa\u011flad\u0131:<\/p>\n<p><strong>Mart 2025:<\/strong> 25,54 $ (k\u0131\u015f sonras\u0131 toparlanma d\u00f6nemi)<br \/> <strong>Nisan 2025:<\/strong> 28,90 $ (1. \u00e7eyrek kazan\u00e7 beklentisi art\u0131\u015f\u0131)<br \/> <strong>May\u0131s 2025:<\/strong> 34,50 $ (g\u00fc\u00e7l\u00fc 1. \u00e7eyrek sonu\u00e7lar\u0131 ile %20 portf\u00f6y b\u00fcy\u00fcmesi)<br \/> <strong>Haziran 2025:<\/strong> 36,80 $ (telif hakk\u0131 modelinin piyasa taraf\u0131ndan tan\u0131nmas\u0131)<br \/> <strong>Temmuz 2025:<\/strong> 37,50 $ (yaz konsolidasyon d\u00f6nemi)<br \/> <strong>A\u011fustos 2025:<\/strong> 35,97 $ (2. \u00e7eyrek kazan\u00e7lar\u0131n\u0131n sindirilmesinden sonra mevcut seviye)<\/p>\n<p>Bu ola\u011fan\u00fcst\u00fc performans birka\u00e7 \u00f6nemli fakt\u00f6re dayan\u0131yor:<\/p>\n<ul>\n<li><strong>Portf\u00f6y gelirleri y\u0131ll\u0131k bazda %20 artarak<\/strong> 2. \u00e7eyrekte 727 milyon $ oldu<\/li>\n<li><strong>Telif hakk\u0131 \u00e7e\u015fitlendirme stratejisi<\/strong> yat\u0131r\u0131mc\u0131 g\u00fcvenini art\u0131r\u0131yor<\/li>\n<li><strong>\u0130\u00e7selle\u015ftirme i\u015flemi tamamland\u0131<\/strong>, i\u015fletme maliyetleri %10&#8217;dan %9-9,5&#8217;a d\u00fc\u015ft\u00fc<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc nakit pozisyonu<\/strong>, 885 milyon $ de\u011ferindeki Imdelltra anla\u015fmas\u0131 gibi stratejik sat\u0131n almalara olanak sa\u011fl\u0131yor<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu Hedefi:<\/strong> 42-46 $ (mevcut 45,33 $ analist konsens\u00fcs\u00fcne dayanarak %25,99 y\u00fckseli\u015f potansiyeli) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/p>\n<p><strong>2026 Tahmini:<\/strong> 48-54 $ (telif portf\u00f6y\u00fcn\u00fcn olgunla\u015fmas\u0131 ve yeni sat\u0131n almalar)<br \/> <strong>2028 Projeksiyonu:<\/strong> 58-65 $ (s\u00fcrekli telif b\u00fcy\u00fcmesi ve piyasa geni\u015flemesi)<br \/> <strong>2030 Vizyonu:<\/strong> 70-80 $ (sekt\u00f6r liderli\u011fi pozisyonu ve k\u00fcresel sa\u011fl\u0131k trendleri)<\/p>\n<p>Y\u00fckseli\u015f beklentisi, Royalty Pharma&#8217;n\u0131n benzersiz i\u015f modeli taraf\u0131ndan destekleniyor &#8211; geli\u015ftirme risklerini \u00fcstlenmeden ba\u015far\u0131l\u0131 ila\u00e7lardan kar ediyorlar. 35&#8217;ten fazla ticari terapi ve 14 geli\u015ftirme a\u015famas\u0131nda aday ile \u015firket, piyasa dalgalanmalar\u0131nda istikrar sa\u011flayan \u00e7oklu gelir ak\u0131\u015flar\u0131na sahip.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p>\n<ul>\n<li><strong>7,8 milyar $ bor\u00e7 y\u00fck\u00fc<\/strong>, y\u0131ll\u0131k 275 milyon $ faiz y\u00fck\u00fcml\u00fcl\u00fc\u011f\u00fc yarat\u0131yor<\/li>\n<li><strong>Promacta gibi ana \u00fcr\u00fcnler i\u00e7in jenerik rekabet tehditleri<\/strong><\/li>\n<li><strong>\u0130la\u00e7 fiyatland\u0131rma politikalar\u0131 (MFN sonu\u00e7lar\u0131) \u00e7evresinde d\u00fczenleyici belirsizlik<\/strong><\/li>\n<li><strong>3 milyar $ agresif hisse geri al\u0131m program\u0131 ile sermaye tahsis zorluklar\u0131<\/strong><\/li>\n<\/ul>\n<p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p>\n<ul>\n<li><strong>Son 885 milyon $ tutar\u0131ndaki Imdelltra telif hakk\u0131 sat\u0131n al\u0131m\u0131<\/strong> (<a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-reports-second-quarter-2025-results\/\">2. \u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>Y\u0131ll\u0131k bazda %20 portf\u00f6y gelir art\u0131\u015f\u0131<\/strong><\/li>\n<li><strong>%2,39-2,45 temett\u00fc verimi<\/strong> ve d\u00fczenli \u00e7eyreklik \u00f6demeler<\/li>\n<li><strong>Biyoteknoloji sekt\u00f6r\u00fcne k\u0131yasla d\u00fc\u015f\u00fck volatilite profili<\/strong> (beta 0,54)<\/li>\n<li><strong>\u0130\u00e7selle\u015ftirme tamamland\u0131<\/strong>, operasyonel maliyetler \u00f6nemli \u00f6l\u00e7\u00fcde azald\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>Dollar-cost averaging ile k\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; zamanlama hatalar\u0131n\u0131 \u00f6nlemek i\u00e7in haftal\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Kas\u0131m kazan\u00e7lar\u0131 \u00f6ncesi cazip giri\u015f noktalar\u0131 i\u00e7in 34-36 $ aras\u0131nda fiyat uyar\u0131lar\u0131 kurun<\/strong><\/li>\n<li><strong>Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %5-10&#8217;unu RPRX&#8217;e ay\u0131r\u0131n<\/strong> &#8211; uygun \u00e7e\u015fitlendirme i\u00e7in<\/li>\n<li><strong>5 Kas\u0131m kazan\u00e7lar\u0131n\u0131 yak\u0131ndan takip edin<\/strong> &#8211; tarihsel olarak en iyi al\u0131m f\u0131rsatlar\u0131n\u0131 yarat\u0131r<\/li>\n<\/ol>\n<p>Mizahi t\u00fcccar bilgeli\u011fi: &#8220;RPRX ticareti yapmak, telif hakk\u0131 toplamak gibidir &#8211; hitlerin gelmeye devam etmesini istersiniz ve d\u00fczenli gelirin tad\u0131n\u0131 \u00e7\u0131kar\u0131rs\u0131n\u0131z. Sadece her \u00e7eyre\u011fin liste ba\u015f\u0131 single olmas\u0131n\u0131 beklemeyin!&#8221;<\/p>\n<h2>\u2705 Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;RPRX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fruluk i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Son onay \u00f6ncesi komisyon oranlar\u0131n\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Fiyat hedefleri ve zarar durdurma uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> &#8211; stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda KYC s\u00fcreci<\/strong> &#8211; tek bir belge ile dakikalar i\u00e7inde do\u011frulama<\/li>\n<li><strong>Y\u00fczlerce para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; kripto paralardan geleneksel bankac\u0131l\u0131\u011fa kadar<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu aray\u00fcz<\/strong> &#8211; piyasalar\u0131 \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in \u00f6zel tasar\u0131m<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, Royalty Pharma gibi \u015firketlerde pozisyon olu\u015fturmak isteyen ve piyasa dinamiklerini \u00f6\u011frenen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Royalty Pharma: Sa\u011fl\u0131k Finansman\u0131n\u0131n Sessiz Devi<\/h2>\n<p>Royalty Pharma, yat\u0131r\u0131mc\u0131lar\u0131n ila\u00e7 inovasyonuna kat\u0131l\u0131m \u015feklini devrim niteli\u011finde de\u011fi\u015ftirdi. Bireysel ila\u00e7 geli\u015ftirmeye bahis yapmak yerine, \u015firket ba\u015far\u0131l\u0131 tedavilerin telif haklar\u0131n\u0131 sat\u0131n alarak \u00e7oklu terap\u00f6tik alanlarda gi\u015fe rekorlar\u0131 k\u0131ran ila\u00e7lardan \u00e7e\u015fitlendirilmi\u015f gelir ak\u0131\u015f\u0131 yarat\u0131yor.<\/p>\n<p>\u015eirket \u015fu anda kanser, nadir hastal\u0131klar ve kronik durumlar i\u00e7in tedaviler dahil olmak \u00fczere 35&#8217;ten fazla ticari \u00fcr\u00fcn\u00fcn haklar\u0131na sahip. Amgen&#8217;in k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an imm\u00fcnoterapisi Imdelltra&#8217;n\u0131n 885 milyon $ tutar\u0131ndaki son sat\u0131n al\u0131m\u0131, d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc ila\u00e7lara stratejik odaklar\u0131n\u0131 g\u00f6steriyor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Royalty Pharma&#8217;n\u0131n portf\u00f6y\u00fc, d\u00fcnya genelinde yakla\u015f\u0131k her 100 hastadan 1&#8217;ini tedavi eden ila\u00e7lardan telif hakk\u0131 al\u0131yor. Gelir modeli, onlar\u0131 geleneksel biyoteknoloji riskleri olmadan sa\u011fl\u0131k inovasyonunun ortaklar\u0131 yap\u0131yor!<\/p>\n"},"faq":[{"question":"Royalty Pharma hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"RPRX\" sembol\u00fcn\u00fc aray\u0131n, limit emri verin ve pozisyonunuzu izleyin."},{"question":"Royalty Pharma'n\u0131n riskleri nelerdir?","answer":"7,8 milyar $ bor\u00e7 y\u00fck\u00fc, jenerik rekabet tehditleri, d\u00fczenleyici belirsizlikler ve agresif hisse geri al\u0131m program\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Royalty Pharma'n\u0131n 2025 fiyat hedefi nedir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat hedefi 42-46 $ aral\u0131\u011f\u0131nda olup, bu g\u00fc\u00e7l\u00fc bir al\u0131m sinyali olarak de\u011ferlendirilir."},{"question":"Yeni ba\u015flayanlar Royalty Pharma hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flay\u0131p, fiyat uyar\u0131lar\u0131 kurarak, portf\u00f6y\u00fcn %5-10'unu ay\u0131rarak ve \u00f6nemli kazan\u00e7 raporlar\u0131n\u0131 takip ederek yat\u0131r\u0131m yapmal\u0131d\u0131rlar."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni ba\u015flayanlar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Royalty Pharma hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"RPRX\" sembol\u00fcn\u00fc aray\u0131n, limit emri verin ve pozisyonunuzu izleyin."},{"question":"Royalty Pharma'n\u0131n riskleri nelerdir?","answer":"7,8 milyar $ bor\u00e7 y\u00fck\u00fc, jenerik rekabet tehditleri, d\u00fczenleyici belirsizlikler ve agresif hisse geri al\u0131m program\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Royalty Pharma'n\u0131n 2025 fiyat hedefi nedir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat hedefi 42-46 $ aral\u0131\u011f\u0131nda olup, bu g\u00fc\u00e7l\u00fc bir al\u0131m sinyali olarak de\u011ferlendirilir."},{"question":"Yeni ba\u015flayanlar Royalty Pharma hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flay\u0131p, fiyat uyar\u0131lar\u0131 kurarak, portf\u00f6y\u00fcn %5-10'unu ay\u0131rarak ve \u00f6nemli kazan\u00e7 raporlar\u0131n\u0131 takip ederek yat\u0131r\u0131m yapmal\u0131d\u0131rlar."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni ba\u015flayanlar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T12:25:47+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-28T12:25:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\",\"name\":\"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-28T12:25:47+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/","og_locale":"tr_TR","og_type":"article","og_title":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-28T12:25:47+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-28T12:25:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/","name":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-28T12:25:47+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-royalty-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Royalty Pharma plc (RPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Royalty Pharma plc (RPRX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":354693,"slug":"how-to-buy-royalty-pharma","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Royalty Pharma plc (RPRX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-royalty-pharma\/"},"pt_AA":{"locale":"pt_AA","id":354691,"slug":"how-to-buy-royalty-pharma","post_title":"Como comprar a\u00e7\u00f5es da Royalty Pharma plc (RPRX) - Investimento em a\u00e7\u00f5es da Royalty Pharma plc (RPRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-royalty-pharma\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/354696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=354696"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/354696\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=354696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=354696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=354696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}